IPAMORELIN vs GHRP-6

In this article, we will review the growth hormone-releasing peptides ipamorelin and GHRP-6. They have many similarities and a few differences. We aim to help you decide which peptide you need for your research. They are both available for sale at Loti Labs, which is a USA based peptide and research company.

A BRIEF INTRODUCTION OF GROWTH HORMONE RELEASING PEPTIDES

Growth hormone-releasing peptides GHRPs are synthetic, non-natural peptides equipped with potent stimulatory effects on Growth hormone secretion in animal test subjects. These synthetic peptides are composed of specific amino acids arranged in sequences that allow them to mimic or influence natural hormone activity. They are classified as synthetic peptides due to their lab-made nature. They have no structural resemblance with Growth Hormone-Releasing Hormone and act through specific receptors present either at the anterior pituitary or hypothalamic level in animals. Unlike GHRPs, growth hormone releasing hormones do not share structural similarities with GHRPs and may work through different mechanisms at the pituitary or hypothalamic level. The GH-releasing activity of GHRPs is noticeable and dose-related after intravenous subcutaneous intranasal and oral administration.

The Growth Hormone Releasing Peptides are affected by glucose, free fatty acids, glucocorticoids, and somatostatin.

Ipamorelin is a third-generation GHRP after GHRP-6, which belongs to the first generation to be extensively studied in animals. It is similar to GHRP-6 because they both release GH at similar rates without the side effects that GHRP-6 exhibits. GHRP-6 causes a release, and an increase in cortisol and prolactin levels, however, ipamorelin only selectively releases GH.

WHAT ARE GHRPs?

Growth Hormone-Releasing Peptides (GHRPs) are a unique class of synthetic peptides designed to stimulate the secretion of growth hormone (GH) from the pituitary gland. Unlike naturally occurring growth hormone releasing hormones, GHRPs such as GHRP-6 and Ipamorelin act by binding to specific receptors in both the pituitary gland and hypothalamus, triggering a cascade that results in increased GH release. This surge in growth hormone production can lead to a variety of physiological effects, including greater lean body mass, enhanced muscle growth, and improved fat loss. As synthetic peptides, GHRPs have been widely studied in scientific research, particularly for their potential to address growth hormone deficiency and to optimize body composition. Their ability to elevate GH levels makes them valuable tools for researchers exploring the mechanisms of muscle growth, fat metabolism, and overall health.

STRUCTURAL DIFFERENCES BETWEEN GHRP6 AND IPAMORELIN

DIFFERENCES

GHRP 6

IPAMORELIN

STRUCTURE

Comparison of Ipamorelin and GHRP-6 peptides showing their roles in growth hormone research.
Comparison chart of Ipamorelin and GHRP-6, highlighting their structures and growth hormone-releasing effects.

AMINO ACID SEQUENCE

His-D-Trp-Ala-Trp-D-Phe-Lys-NH2

H-Aib-His-D-2Nal-D-Phe-Lys-NH2

MOLECULAR FORMULA

C46H56N12O6

C38H49N9O5

MOLECULAR WEIGHT

873 g/mol

711.9 g/mol

Mechanism of Action: GHRP-6 vs. Ipamorelin in Growth Hormone Release

Studies in animal test subjects show that both GHRP-6 and ipamorelin, which are growth hormone secretagogues (GH secretagogues), stimulate Ghrelin, “the hunger hormone,” through its ghrelin receptor. Activation of this receptor stimulates GH release and enhances growth hormone secretion, contributing to pulsatile GH release and a robust GH response by acting at the level of the pituitary or hypothalamus through a specific receptor different from that of the endogenous Growth Hormone-Releasing Hormone GHRH. This specific receptor is known as the growth hormone secretagogue receptor (GHS-R). The effects of GHRP-6 on GH release were achieved using various doses and administration routes. These peptides also play a role in energy homeostasis and appetite regulation.

Іn соntrаѕt tо GHRP-6, Iраmоrеlіn іѕ mоrе ѕеlесtіvе іn іtѕ асtіvаtіоn because it doesn’t have any effect on cortisol or prolactin. It іѕ mеtаbоlіzеd ѕlоwеr thаn GHRP-6, mаkіng іt mоrе ѕtаblе аnd thеrеbу еffесtіvе fоr lоngеr. Increased GH production from these secretagogues leads to higher levels of insulin-like growth factor, which mediates many of the anabolic effects associated with growth hormone therapy.

Benefits and Effects of Ipamorelin

Ipamorelin is a potent growth hormone-releasing peptide (GHRP) that offers several notable benefits and effects:

  1. Enhanced Muscle Growth: Ipamorelin stimulates the release of growth hormone, which promotes muscle growth and development. Increased protein synthesis and lean muscle mass are key outcomes, and these peptides help preserve muscle mass and lean mass, making them valuable tools for researchers studying muscle hypertrophy and skeletal muscle adaptation.
  2. Improved Recovery: By enhancing growth hormone release, Ipamorelin helps improve recovery times after exercise. These peptides also support tissue repair and muscle and connective tissue regeneration, allowing athletes and test subjects to train more frequently and with greater intensity, facilitating better performance and muscle growth.
  3. Increased Bone Density: Research indicates that Ipamorelin can increase bone density, which is crucial for reducing the risk of osteoporosis and fractures. These effects are particularly relevant for hypogonadal males and patients seeking improvements in bone health, and testosterone therapy is sometimes used in parallel. This effect is especially beneficial in studies focused on bone health and aging.
  4. Improved Sleep Quality: Ipamorelin has been shown to improve sleep quality, which is essential for muscle recovery and overall well-being. Improving sleep quality also contributes to anti aging effects, with better sleep supporting enhanced muscle growth and cognitive function.
  5. Enhanced Skin Elasticity: Ipamorelin has also been shown to improve skin elasticity, reducing the appearance of fine lines and wrinkles. This makes it a subject of interest in studies related to aging and dermatology.

Ipamorelin and GHRP-6 can reduce body fat, fat mass, and visceral fat, while promoting the breakdown of stored fat, leading to improved body composition. Changes in body weight and weight gain may occur due to shifts in muscle and fat mass, with these peptides supporting increases in muscle mass and lean mass while minimizing fat accumulation.

Increased GH secretion and elevated GH levels from these peptides can influence glucose levels and insulin sensitivity, which are important considerations for metabolic syndrome and overall metabolic health.

Unlike exogenous GH therapy, Ipamorelin and related peptides mimic natural, pulsatile GH secretion, potentially reducing side effects and offering a more physiological approach for patients seeking improvements in muscle mass, body composition, and anti aging effects.

Disclaimer: Ipamorelin and GHRP-6 are classified as research chemicals and are not approved for human consumption.

COMPARING AND CONTRASTING THE EFFECTS OF IPAMORELIN AND GHRP-6 TO ENHANCE MUSCLE GROWTH

Ipamorelin and GHRP-6 have similar effects on animal test subjects but differ structurally. They both act on the pituitary gland to release growth hormone, and their ability to stimulate pulsatile GH release is important for maintaining pituitary sensitivity and optimizing results. The release of growth hormone by these peptides can lead to increases in lean mass and muscle mass, while also reducing fat mass, which is beneficial for body composition. This makes them attractive to fitness enthusiasts seeking improvements in muscle growth, fat loss, and overall body composition. Their differences are listed in the table below.

GHRP-6

IPAMORELIN

Effect on hunger

Increases hunger markedly. GHRP-6 has a pronounced effect on appetite regulation, which can impact energy homeostasis and body weight.

Doesn’t promote hunger

Effect on growth hormone release

More

Less

Effect on prolactin and cortisol release

Less control

None observed

Potency

Same

Same

Half-life

Shorter half-life

Longer half-life

GHRP-2: ANOTHER GROWTH HORMONE RELEASING PEPTIDE

GHRP-2 is another member of the growth hormone-releasing peptide family, recognized for its potent ability to stimulate GH release. Structurally similar to GHRP-6, GHRP-2 binds to the ghrelin receptor, activating the pituitary gland to secrete growth hormone. This action can result in notable improvements in muscle growth, fat loss, and bone density, making GHRP-2 a popular choice in both research and clinical settings. Studies have demonstrated that GHRP-2 effectively raises GH levels in healthy individuals as well as those with GH deficiency. However, it is important to consider that GHRP-2 can also elevate cortisol and prolactin levels, which may have unwanted effects if not properly managed. As with other growth hormone releasing peptides, careful monitoring of GH, cortisol, and prolactin levels is recommended to maximize benefits and minimize risks.

THE ROLE OF ANDROGEN RECEPTORS IN GHRP ACTIVITY

Androgen receptors are increasingly recognized for their involvement in the activity of growth hormone releasing peptides. Research suggests that GHRPs like GHRP-6 and Ipamorelin may interact with androgen receptors, contributing to enhanced GH release and supporting muscle growth. This interaction may also influence testosterone levels, potentially benefiting muscle development and libido. However, the precise mechanisms by which GHRPs affect androgen receptors remain an area of ongoing investigation. It is important to note that the degree of interaction with androgen receptors can vary between different GHRPs, which may account for differences in their effects on muscle growth and hormonal balance.

IMPACT ON BONE DENSITY

One of the notable benefits of growth hormone releasing peptides is their positive impact on bone density. Growth hormone plays a vital role in bone growth and maintenance, and increased GH levels—stimulated by peptides like GHRP-6 and Ipamorelin—have been shown to enhance bone density in both animal and human studies. Improved bone density is particularly valuable for reducing the risk of osteoporosis and fractures, especially in aging populations. While the exact biological pathways through which GHRPs influence bone density are still being explored, current evidence supports their potential as research tools for studying bone health and the prevention of degenerative bone conditions.

GHRP-2: ANOTHER GROWTH HORMONE RELEASING PEPTIDE

GHRP-2 is another member of the growth hormone-releasing peptide family, recognized for its potent ability to stimulate GH release. Structurally similar to GHRP-6, GHRP-2 binds to the ghrelin receptor, activating the pituitary gland to secrete growth hormone. This action can result in notable improvements in muscle growth, fat loss, and bone density, making GHRP-2 a popular choice in both research and clinical settings. Studies have demonstrated that GHRP-2 effectively raises GH levels in healthy individuals as well as those with GH deficiency. However, it is important to consider that GHRP-2 can also elevate cortisol and prolactin levels, which may have unwanted effects if not properly managed. As with other growth hormone releasing peptides, careful monitoring of GH, cortisol, and prolactin levels is recommended to maximize benefits and minimize risks.

THE ROLE OF ANDROGEN RECEPTORS IN GHRP ACTIVITY

Androgen receptors are increasingly recognized for their involvement in the activity of growth hormone releasing peptides. Research suggests that GHRPs like GHRP-6 and Ipamorelin may interact with androgen receptors, contributing to enhanced GH release and supporting muscle growth. This interaction may also influence testosterone levels, potentially benefiting muscle development and libido. However, the precise mechanisms by which GHRPs affect androgen receptors remain an area of ongoing investigation. It is important to note that the degree of interaction with androgen receptors can vary between different GHRPs, which may account for differences in their effects on muscle growth and hormonal balance.

IMPACT ON BONE DENSITY

One of the notable benefits of growth hormone releasing peptides is their positive impact on bone density. Growth hormone plays a vital role in bone growth and maintenance, and increased GH levels—stimulated by peptides like GHRP-6 and Ipamorelin—have been shown to enhance bone density in both animal and human studies. Improved bone density is particularly valuable for reducing the risk of osteoporosis and fractures, especially in aging populations. While the exact biological pathways through which GHRPs influence bone density are still being explored, current evidence supports their potential as research tools for studying bone health and the prevention of degenerative bone conditions.

Proper subcutaneous injection technique is essential to minimize local reactions and ensure consistent dosing.

By following these strategies, researchers can maximize the benefits of Ipamorelin and GHRP-6 while minimizing potential side effects, ensuring the integrity and success of their studies.

STACKING GHRPs WITH OTHER PEPTIDES

Combining, or “stacking,” growth hormone releasing peptides with other peptides can amplify their effects on GH release and muscle growth. For instance, using GHRP-6 alongside Ipamorelin may result in a more significant increase in GH levels than either peptide alone. Additionally, stacking GHRPs with peptides such as CJC-1295 can further enhance muscle growth and promote fat loss, offering a synergistic approach for researchers investigating body composition and metabolic health. However, it is important to recognize that stacking peptides can also raise the risk of side effects, including elevated cortisol and prolactin levels. Careful consideration of dosing, timing, and individual response is essential to achieve a significant increase in GH levels while minimizing potential adverse effects. As always, monitoring hormone levels and consulting with knowledgeable professionals is recommended when exploring peptide combinations in research settings.

Conclusion: Key Insights on Ipamorelin vs. GHRP-6 Peptides

GHRP-6 is one of the first GHRP-6 synthesized, and is widely considered to be the most effective of the growth hormone-releasing peptides, but the choice between GHRP-6 and ipamorelin depends on the outcome you want to achieve. Whatever your choice is, Loti Labs assures you of the highest quality USA-made peptides.

LOOKING FOR WHERE TO BUY RESEARCH PEPTIDES?

Ipamorelin and GHRP-6 can both be purchased from Loti Labs. These peptides are considered research peptides, which are used in scientific studies to explore their effects on growth hormone stimulation and other bodily functions. It is important to buy peptides that are USA-made for the integrity of your research. GHRP-2, Ipamorelin and GHRP-6 sold from Loti Labs are tested through HPLC and Mass spectrometry to ensure quality. Ipamorelin and GHRP-6 are available in lyophilized powder form in 2mg and 5mg vials, respectively. Buy your peptides from is today!

  1. Camanni, Franco & Ghigo, Ezio & Arvat, Emanuela. (1998). Growth Hormone-Releasing Peptides and Their Analogs. Frontiers in neuroendocrinology. 19. 47-72. 10.1006/frne.1997.0158.
  2. Wu D, Chen C, Zhang J, Bowers CY, Clarke IJ. The effects of GH-releasing peptide-6 (GHRP-6) and GHRP-2 on intracellular adenosine 3′,5′-monophosphate (cAMP) levels and GH secretion in ovine and rat somatotrophs. J Endocrinol. 1996;148(2):197–205. doi:10.1677/joe.0.1480197
  3. Rogério G. Gondo, Manuel H. Aguiar-Oliveira, César Y. Hayashida, Sergio P. A. Toledo, Neusa Abelin, Michael A. Levine, Cyril Y. Bowers, Anita H. O. Souza, Rossana M. C. Pereira, Norma L. Santos, Roberto Salvatori, Growth Hormone-Releasing Peptide-2 Stimulates GH Secretion in GH-Deficient Patients with Mutated GH-Releasing Hormone Receptor, The Journal of Clinical Endocrinology & Metabolism, Volume 86, Issue 7, 1 July 2001, Pages 3279–3283, https://doi.org/10.1210/jcem.86.7.7694
  4. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. doi:10.1530/eje.0.1390552
  5. Johansen PB, Nowak J, Skjaerbaek C, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106–113. doi:10.1054/ghir.1999.9998
Scroll to Top